This is done by reviewing aberrant 5-HT1A receptor functioning in epilepsy, noting that 5-MeO-DMT has notable 5-HT1A receptor agonist properties—and then comparing the acute behavioral and subjective effects induced by 5-MeO-DMT to those that occur in seizures.